Natural Killer Cells in SARS-CoV-2-Vaccinated Subjects with Increased Effector Cytotoxic CD56dim Cells and Memory-Like CD57+NKG2C+CD56dim Cells

Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience (Landmark. Print) Vol. 28; no. 7; p. 156
Main Authors Gentili, Valentina, Bortolotti, Daria, Morandi, Luca, Rizzo, Sabrina, Schiuma, Giovanna, Beltrami, Silvia, Casciano, Fabio, Papi, Alberto, Contoli, Marco, Zauli, Giorgio, Rizzo, Roberta
Format Journal Article
LanguageEnglish
Published IMR Press 01.07.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production. Results: The booster dose caused early NK CD56dim subset activation and memory-like phenotype. Conclusions: We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose.
AbstractList Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity. Methods: Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production. Results: The booster dose caused early NK CD56dim subset activation and memory-like phenotype. Conclusions: We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose.
The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity.BACKGROUNDThe infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether vaccination has worked by eliciting robust protective innate immune responses with high affinity.Twenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production.METHODSTwenty healthy volunteers received three doses of Comirnaty (Pfizer Australia Pty Ltd.) and were evaluated 9 months after the second vaccination and 1 month after the booster dose. The exclusion criteria were the presence of adverse effects following the vaccination, a history of smoking, and heterologous immunization. The inclusion criteria were the absence of prior Coronavirus Disease (COVID)-19 history, the absence of adverse effects, and the absence of comorbidities. Specific phenotype and levels of CD107a and granzyme production by blood NK (natural killer) cells were analyzed after exposure to SARS-CoV-2 spike antigen (Wuhan, Alpha B.1.1.7, Delta B.1.617.2, and Omicron B1.1.529 variants), and related with anti-SARS-CoV-2 antibody production.The booster dose caused early NK CD56dim subset activation and memory-like phenotype.RESULTSThe booster dose caused early NK CD56dim subset activation and memory-like phenotype.We report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose.CONCLUSIONSWe report the relevance of the innate immune response, especially NK cells, to SARS-CoV-2 vaccines to guarantee efficient protection against the infection following a booster dose.
Author Contoli, Marco
Zauli, Giorgio
Gentili, Valentina
Rizzo, Sabrina
Casciano, Fabio
Bortolotti, Daria
Schiuma, Giovanna
Beltrami, Silvia
Papi, Alberto
Morandi, Luca
Rizzo, Roberta
Author_xml – sequence: 1
  givenname: Valentina
  orcidid: 0000-0003-4572-5497
  surname: Gentili
  fullname: Gentili, Valentina
– sequence: 2
  givenname: Daria
  orcidid: 0000-0003-4496-9561
  surname: Bortolotti
  fullname: Bortolotti, Daria
– sequence: 3
  givenname: Luca
  orcidid: 0000-0001-7264-206X
  surname: Morandi
  fullname: Morandi, Luca
– sequence: 4
  givenname: Sabrina
  orcidid: 0000-0002-9246-136X
  surname: Rizzo
  fullname: Rizzo, Sabrina
– sequence: 5
  givenname: Giovanna
  orcidid: 0000-0003-4652-5550
  surname: Schiuma
  fullname: Schiuma, Giovanna
– sequence: 6
  givenname: Silvia
  orcidid: 0000-0002-5923-9265
  surname: Beltrami
  fullname: Beltrami, Silvia
– sequence: 7
  givenname: Fabio
  orcidid: 0000-0002-6431-3335
  surname: Casciano
  fullname: Casciano, Fabio
– sequence: 8
  givenname: Alberto
  orcidid: 0000-0002-6924-4500
  surname: Papi
  fullname: Papi, Alberto
– sequence: 9
  givenname: Marco
  orcidid: 0000-0002-2731-5809
  surname: Contoli
  fullname: Contoli, Marco
– sequence: 10
  givenname: Giorgio
  orcidid: 0000-0002-3750-8698
  surname: Zauli
  fullname: Zauli, Giorgio
– sequence: 11
  givenname: Roberta
  orcidid: 0000-0001-9507-9126
  surname: Rizzo
  fullname: Rizzo, Roberta
BookMark eNp1kU9v1DAQxSPUSpS2R-45IlUp_m_nWIW2rLoUiYVeLcceg5dsXGyvYD8FXxnTLSCQOM3o-TfvaTzPmoM5ztA0zzE6pxgp-nJ97seJKCQxF0-aIyKF6oTo1cGvXiL8tDnNeY0QIj3GPVdHzfdbU7bJTO1NmCZI7QDTlNswt6uLd6tuiHcd6e6MtWE2BVy72o5rsCW3X0P51C5mm8Dkql96X-VY53cllvgt2HZ4xYULm0dHM7v2DWxi2nXL8Bl-vsqz25trMpz9BZ40h95MGU4f63Hz4ery_fC6W769XgwXy85SyUvHHbOKjKOihDlcdwHlhOu9AQqu_gYCDhQb1fPReOqYB8SslNJ44gA4o8fNYu_rolnr-xQ2Ju10NEE_CDF91CaVYCfQbGSkRvmx55SZXo01zyIpkGCYYUqr14u9132KX7aQi96EbOs2Zoa4zZooxoRUiouKdnvUpphzAv87GiP9cEe91n_uWHn6D29DMSXEuSQTpv9M_QAq8KEt
CitedBy_id crossref_primary_10_31083_j_fbl2903107
crossref_primary_10_1186_s12985_024_02287_0
Cites_doi 10.1001/jama.2021.7563
10.1038/s41467-023-35862-0
10.3390/cells9091975
10.1016/j.jim.2004.08.008
10.1038/s41423-020-0402-2
10.1038/s41586-021-03738-2
10.1111/j.1365-2567.2008.03027.x
10.1016/j.cellimm.2021.104454
10.1046/j.1365-2567.1999.00738.x
10.1056/NEJMoa2115481
10.1084/jem.20122571
10.1038/s41423-020-0483-y
10.1016/j.chom.2020.04.009
10.3390/immuno1030021
10.3390/v9120367
10.1038/ni1395
10.1016/j.ijid.2022.06.020
10.3389/fimmu.2020.01441
10.1016/S2666-5247(21)00069-0
10.1056/NEJMoa2034577
10.1089/152581600419116
10.1182/blood-2010-04-282301
10.1126/sciimmunol.abd6832
10.1016/B978-0-12-370454-2.00015-6
10.3389/fimmu.2022.888313
10.3390/microorganisms10030501
10.1038/s41577-021-00526-x
10.1038/s41591-020-0944-y
10.3389/fimmu.2022.798813
10.1038/cdd.2015.3
10.1111/j.1365-2567.2009.03123.x
10.1016/j.coi.2006.05.002
ContentType Journal Article
Copyright 2023 The Author(s). Published by IMR Press.
Copyright_xml – notice: 2023 The Author(s). Published by IMR Press.
DBID AAYXX
CITATION
7X8
DOA
DOI 10.31083/j.fbl2807156
DatabaseName CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2768-6698
ExternalDocumentID oai_doaj_org_article_4b422bbfb9534a98b111c07606414133
10_31083_j_fbl2807156
GroupedDBID 3IV
53G
AAFWJ
AAYXX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
7X8
ID FETCH-LOGICAL-c375t-5d4c82bb8324d1119e8d6d9fae3ed0830e5e31a895baf3d4fe04c777af2dee543
IEDL.DBID DOA
ISSN 2768-6701
2768-6698
IngestDate Wed Aug 27 01:20:06 EDT 2025
Fri Jul 11 07:30:08 EDT 2025
Thu Apr 24 23:02:25 EDT 2025
Tue Jul 01 01:37:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License https://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-5d4c82bb8324d1119e8d6d9fae3ed0830e5e31a895baf3d4fe04c777af2dee543
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9246-136X
0000-0002-6431-3335
0000-0003-4572-5497
0000-0003-4652-5550
0000-0003-4496-9561
0000-0001-9507-9126
0000-0002-6924-4500
0000-0001-7264-206X
0000-0002-5923-9265
0000-0002-2731-5809
0000-0002-3750-8698
OpenAccessLink https://doaj.org/article/4b422bbfb9534a98b111c07606414133
PQID 2844678856
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_4b422bbfb9534a98b111c07606414133
proquest_miscellaneous_2844678856
crossref_primary_10_31083_j_fbl2807156
crossref_citationtrail_10_31083_j_fbl2807156
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationTitle Frontiers in bioscience (Landmark. Print)
PublicationYear 2023
Publisher IMR Press
Publisher_xml – name: IMR Press
References ref13
ref12
ref15
ref14
ref31
ref30
ref11
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref2
  doi: 10.1001/jama.2021.7563
– ident: ref21
  doi: 10.1038/s41467-023-35862-0
– ident: ref32
  doi: 10.3390/cells9091975
– ident: ref31
  doi: 10.1016/j.jim.2004.08.008
– ident: ref12
  doi: 10.1038/s41423-020-0402-2
– ident: ref3
  doi: 10.1038/s41586-021-03738-2
– ident: ref10
  doi: 10.1111/j.1365-2567.2008.03027.x
– ident: ref29
  doi: 10.1016/j.cellimm.2021.104454
– ident: ref30
  doi: 10.1046/j.1365-2567.1999.00738.x
– ident: ref4
  doi: 10.1056/NEJMoa2115481
– ident: ref27
  doi: 10.1084/jem.20122571
– ident: ref16
  doi: 10.1038/s41423-020-0483-y
– ident: ref13
  doi: 10.1016/j.chom.2020.04.009
– ident: ref25
  doi: 10.3390/immuno1030021
– ident: ref24
  doi: 10.3390/v9120367
– ident: ref28
  doi: 10.1038/ni1395
– ident: ref20
  doi: 10.1016/j.ijid.2022.06.020
– ident: ref11
  doi: 10.3389/fimmu.2020.01441
– ident: ref1
  doi: 10.1016/S2666-5247(21)00069-0
– ident: ref17
  doi: 10.1056/NEJMoa2034577
– ident: ref19
  doi: 10.1089/152581600419116
– ident: ref26
  doi: 10.1182/blood-2010-04-282301
– ident: ref14
  doi: 10.1126/sciimmunol.abd6832
– ident: ref8
  doi: 10.1016/B978-0-12-370454-2.00015-6
– ident: ref9
  doi: 10.3389/fimmu.2022.888313
– ident: ref23
  doi: 10.3390/microorganisms10030501
– ident: ref22
  doi: 10.1038/s41577-021-00526-x
– ident: ref15
  doi: 10.1038/s41591-020-0944-y
– ident: ref18
  doi: 10.3389/fimmu.2022.798813
– ident: ref6
  doi: 10.1038/cdd.2015.3
– ident: ref7
  doi: 10.1111/j.1365-2567.2009.03123.x
– ident: ref5
  doi: 10.1016/j.coi.2006.05.002
SSID ssj0002911958
Score 2.2528272
Snippet Background: The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown...
The infection and negative effects of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus) virus are mitigated by vaccines. It is unknown whether...
SourceID doaj
proquest
crossref
SourceType Open Website
Aggregation Database
Enrichment Source
Index Database
StartPage 156
SubjectTerms innate response
nk cell
sars-cov-2
vaccine
Title Natural Killer Cells in SARS-CoV-2-Vaccinated Subjects with Increased Effector Cytotoxic CD56dim Cells and Memory-Like CD57+NKG2C+CD56dim Cells
URI https://www.proquest.com/docview/2844678856
https://doaj.org/article/4b422bbfb9534a98b111c07606414133
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG4kIHgRn7i-aEG8aJudfk4f42oMxuzBmJDb0E-YuM6IOwH3V_iXreqZxAURL15nah5UVVdVd1d_HyHPveYymZyZ8BVnUjvOLJ8LpmwMkptcZ4HnnY-W-uBEfjhTZ1tUX9gTNsIDj4rblV5y7n32VgnpbO1hcAbcTtKyggBccD4h521NpjAGc4tQZoWODuppps28GgE2oZqpxe756-xXiANTIXH1VkIquP1_hOWSa_ZvkZtTkUj3xp-7Ta6l7g65PtJGbu6Sn0tX0DLoYTnIRxdptVrTtqPHe5-O2aI_ZZyduhDaDgrJSCE24GLLmuKaK4WAgH3ocH0ELu7h-c3QD_2PNtDFW6Vj-3V6o-siPcJO3A372H5JeNe8XB6-x7XVbcF75GT_3efFAZuIFVgQRg1MRRlqUCqMZhlBnzbVUUebXRIpgn7mSSVRudoq78BWMqe5DMYYl3lMSUlxn-x0fZceEKpjMM6KmCwPMnPjoIJL0ULeU5XnTs3Iq0vtNmFCHUfyi1UDs49iDJh-_DbGjLy4Ev82wm38TfANmupKCFGyywXwnWbyneZfvjMjzy4N3cCowq0S16X-Yt1A0oYMUtdKP_wfH3pEbiBN_djm-5jsDN8v0hMoZgb_tPjtL9XK7Bs
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Killer+Cells+in+SARS-CoV-2-Vaccinated+Subjects+with+Increased+Effector+Cytotoxic+CD56dim+Cells+and+Memory-Like+CD57%2BNKG2C%2BCD56dim+Cells&rft.jtitle=Frontiers+in+bioscience+%28Landmark.+Print%29&rft.au=Valentina+Gentili&rft.au=Daria+Bortolotti&rft.au=Luca+Morandi&rft.au=Sabrina+Rizzo&rft.date=2023-07-01&rft.pub=IMR+Press&rft.issn=2768-6701&rft.volume=28&rft.issue=7&rft.spage=156&rft_id=info:doi/10.31083%2Fj.fbl2807156&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_4b422bbfb9534a98b111c07606414133
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2768-6701&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2768-6701&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2768-6701&client=summon